Archives
-
MAPK10–KRT16 Axis in NSCLC Metastasis
2026-09-12
The reference study identifies a phosphorylation-dependent MAPK10–KRT16–RNF213 pathway that limits non-small cell lung cancer metastasis by promoting KRT16 ubiquitination and degradation. Its combination of kinase-mechanism experiments, metastatic phenotyping, pharmacologic rescue, and clinical correlation provides a framework for studying post-translational control of keratin-driven tumor behavior.
-
Naftifine HCl: Applied Assays and Optimization
2026-09-11
Build more informative antifungal experiments with Naftifine HCl by pairing growth inhibition with sterol, morphology, and selectivity readouts. This research-use workflow also adapts the reference study’s orthogonal, state-resolved design without confusing fungal target biology with muscle regeneration pathways.
-
Palonosetron in CINV: Evidence and Clinical Position
2026-09-11
Fabi and Malaguti’s 2013 review synthesized pharmacology, clinical evidence, guideline placement, and emerging combination strategies for palonosetron in radio- and chemotherapy-induced nausea and vomiting. Its main contribution was to clarify why high receptor affinity and prolonged exposure were especially relevant to delayed chemotherapy-induced nausea and vomiting, while identifying unresolved questions in multi-day treatment and breakthrough control.
-
Firefly Luciferase mRNA for LNP Assay Design
2026-09-10
Build more informative reporter workflows with Cap1-capped, 5-moUTP modified mRNA for translation, delivery, stability, and imaging studies. This guide connects practical Firefly Luciferase mRNA handling with emerging evidence on buffer selection for nebulized lipid nanoparticles.
-
Reelin–SFK Signaling in Ketamine Antidepressant Action
2026-09-10
The 2021 PNAS study identifies Reelin–Apoer2–Src family kinase signaling as a permissive pathway for ketamine-induced hippocampal synaptic plasticity and antidepressant-related behavioral effects. Its genetic and pharmacological experiments suggest that impaired baseline NMDA receptor function, rather than a failure of ketamine to alter DAB1 phosphorylation, may contribute to ketamine nonresponsiveness.
-
Fast-Dissociating Antibodies for Single-Molecule Imaging
2026-09-09
Miyoshi and colleagues developed a semi-automated single-molecule TIRF assay to identify specific antibodies that dissociate rapidly, screening directly from hybridoma cultures rather than relying only on conventional endpoint assays. The resulting Fab probes supported multiplex super-resolution imaging and revealed rapid espin turnover within long-lived actin cores of inner-ear hair-cell stereocilia.
-
NF 449: Purinergic Receptor Antagonist Workflow
2026-09-09
NF 449 enables controlled separation of ATP-driven P2X1 signaling from broader platelet purinergic responses. This workflow guide connects receptor profiling, calcium-flux assays, collagen-induced platelet aggregation, and thrombosis models with practical optimization and troubleshooting advice.
-
Alpha-Ketoglutarate: TCA and Immune Metabolism
2026-09-08
Alpha-ketoglutarate is a central TCA-cycle intermediate that connects carbon flux, nitrogen handling, and enzyme-system research. Recent cholangiocarcinoma evidence links α-KGA accumulation to OXGR1-MAPK signaling and reduced macrophage antigen presentation, but this mechanistic finding does not establish alpha-ketoglutarate as an approved therapy.
-
DDX3 Helicase Domain: Crystallization and X-ray Insights
2026-09-08
Rodamilans and Montoya established an experimental route to produce and crystallize the human DDX3 helicase domain, obtaining synchrotron diffraction to 2.2 Å. Although the study stopped at preliminary crystallographic analysis, its construct design and crystal parameters provided an important foundation for investigating DDX3 structure, RNA remodeling, and disease-associated functions.
-
Deuterated CYP51 Inhibitors: C52 and Antifungal Design
2026-09-07
The reference study used molecular hybridization and deuterium substitution to develop diphenyl azole alcohol-based CYP51 inhibitors, identifying compound C52 as a broad-spectrum preclinical lead. C52 combined antifungal, antibiofilm, antimorphogenic, pharmacokinetic, and in vivo activity, although further work is needed to establish its clinical relevance and differentiation from existing agents such as Oteseconazole.
-
Solanesol (B8776): Practical Workflow Guide
2026-09-07
Solanesol (B8776) provides a defined hydrophobic polyisoprenoid alcohol for biochemical workflows that require controlled DMSO-based preparation and solvent-matched controls. It should not be introduced directly into water- or ethanol-based systems, and it is intended only for scientific research rather than diagnostic, clinical, or medical use.
-
3-Methyladenine and the Cuproptosis–Autophagy Axis
2026-09-05
3-Methyladenine is more than a conventional autophagy inhibitor: its time-dependent effects on PI3K signaling create a useful perturbation framework for studying how autophagy intersects with copper-driven cell death. This article translates recent cuproptosis findings into practical experimental strategy while defining the opportunities and limitations of using 3-MA in cancer and migration research.
-
Cytochalasin B (NSC 107658) Workflow Guide
2026-09-04
Build more interpretable actin-perturbation experiments with Cytochalasin B, from reversible motility assays to orthogonal cytotoxicity controls. This workflow positions NSC 107658 as a practical cytoskeletal research tool and drug-discovery probe rather than a standalone viability reagent.
-
Ginsenoside Rg1 and Anesthesia-Induced Neuroimmune Disruptio
2026-09-04
A 2025 Journal of Ethnopharmacology study shows that Ginsenoside Rg1 counteracts prolonged isoflurane-associated behavioral, inflammatory, synaptic, intestinal-barrier, and immune abnormalities in mice. Its most important mechanistic advance is evidence that regulatory T cells are required for restoring gut–immune–brain communication, although translation beyond this preclinical model remains unresolved.
-
Pseudo-UTP: Designing Better mRNA Experiments
2026-09-03
Pseudo-UTP enables controlled mRNA synthesis with pseudouridine modification for studies of RNA stability, translation, and immune compatibility. This guide connects nucleotide selection to assay design and interprets what vaccine evidence can—and cannot—establish.